GE HealthCare stock gains as SOFIE deal expands PET reach

Published on 10/05/2026 at 20:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

GE HealthCare stock traded at USD 65.61 on October 5, 2026, as the company agreed to buy SOFIE Biosciences for USD 945 million. The deal adds 15 U.S. sites and 21 cyclotrons.

GE HealthCare, US36266G1076, Illustration mit AI erstellt.

GE HealthCare stock (ISIN US36266G1076) traded at USD 65.61 on Nasdaq at 2:17 p.m. ET on October 5, 2026, up 2.06 percent from the previous close of USD 64.29. The company announced a USD 945 million cash acquisition that expands its pharmaceutical diagnostics platform into the final mile of U.S. PET radiopharmaceutical supply.

SOFIE deal adds PET capacity

According to GE HealthCare on October 5, 2026, SOFIE Biosciences will join the Pharmaceutical Diagnostics segment after the transaction closes, subject to regulatory approvals and other conditions. The expected closing period is the first half of 2027.

SOFIE operates 15 U.S. contract manufacturing sites with 21 cyclotrons, giving GE HealthCare a manufacturing and distribution network for time-sensitive PET products. The agreement also provides U.S. rights to FAPI-74, a Phase III PET radiotracer for which GE HealthCare already holds rights outside the United States, Reuters reported on October 5, 2026.

Quarterly figures set the baseline

GE HealthCare reported USD 5.295 billion in second-quarter 2026 revenue and diluted EPS of USD 1.24 in the latest standardized quarterly figures. Revenue increased from USD 5.131 billion in the first quarter, while diluted EPS rose from USD 0.85, a sequential comparison that puts the acquisition in the context of improving quarterly earnings.

A separate report on the second-quarter release cited adjusted EPS of USD 1.13, revenue of USD 5.29 billion and revenue growth of 5.8 percent year over year. Investing.com reported that the revenue figure exceeded the cited consensus estimate of USD 5.264 billion.

Analysts see room above Nasdaq price

Consensus data from MarketBeat show a Moderate Buy rating based on 11 Buy and 11 Hold ratings, with an average price target of USD 78.39. That target lies 19.5 percent above the USD 65.61 Nasdaq price, while the published 52-week range runs from USD 58.75 to USD 89.77.

The acquisition's financial effect is a forward-looking consideration rather than a reported result: GE HealthCare said it expects SOFIE to be accretive to revenue growth, adjusted EBIT margin and adjusted EPS in the first full year of ownership. That creates a measurable checkpoint for investors once the deal closes and SOFIE becomes part of PDx.

GE HealthCare stock trades higher

GE HealthCare stock was last at USD 65.61 on Nasdaq at 2:17 p.m. ET on October 5, 2026. Its market capitalization was USD 29.6 billion, with 1,491,438 shares traded at that time.